Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:
A new study shows that the drug pembrolizomab significantly prolongs survival in patients with metastatic melanoma, regardless of whether their tumors have mutations in the BRAF gene or if they’ve had prior treatment with targeted therapy.
Go to full article published by OncLive.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.